BACKGROUND/AIM: To evaluate the effectiveness of curative (chemo)radiotherapy in patients with nasopharyngeal carcinoma and to identify prognostic factors influencing treatment outcomes. PATIENTS AND METHODS: We conducted a retrospective study of 73 consecutive patients, treated with definitive (chemo)radiotherapy from 2002 to 2019 (median stage III/IV 78%). The median total dose of radiotherapy achieved was 70 Gy. Concomitant chemotherapy was given to 82% of patients. RESULTS: The five- and ten-year locoregional controls were 73% and 72%, respectively; the five- and ten-year distant controls were 93% and 93%, respectively. The five- and ten-year overall survival rates were 46% and 34%, respectively. A multivariate analysis identified age, smoking, and the initial response to treatment as the strongest prognostic factors in predicting survival. CONCLUSION: Smoking ≤5 years before starting curative (chemo)radiotherapy for nasopharyngeal carcinoma was shown to be an independent negative prognostic factor for overall survival with a four-fold higher risk of death compared to non-smokers.
OBJECTIVES: Patients with nasopharyngeal cancer are candidates for proton radiotherapy due to large and comprehensive target volumes, and the necessity for sparing of healthy tissues. The aim of this work is to evaluate treatment outcome and toxicity profile of patients treated with proton pencil-beam scanning radiotherapy. MATERIALS AND METHODS: Between Jan 2013 and June 2018, 40 patients were treated for nasopharyngeal cancer (NPC) with IMPT (proton radiotherapy with modulated intensity). Median age was 47 years and the majority of patients had locally advanced tumors (stage 2-8 patients. (20%); stage 3-18 patients (45%); stage 4A-10 patients. (25%); stage 4B-4 patients. (10%). Median of total dose was 74 GyE (70-76 GyE) in 37 fractions (35-38). Bilateral neck irradiation was used in all cases. Concomitant chemotherapy was applied in 34 cases. (85%). Median follow-up time was 24 (1.5-62) months. RESULTS: Two-year overall survival (OS), disease-free survival (DFS), and local control (LC) were 80%, 75%, and 84%, respectively. Acute toxicity was generally mild despite large target volumes and concurrent application of chemotherapy with skin toxicity and dysphagia reported as the most frequent acute side effects. The insertion of a percutaneous endoscopic gastrectomy (PEG) was necessary in four cases (10%). Serious late toxicity (G > 3. RTOG) was observed in two patients (5%) (dysphagia and brain necrosis). CONCLUSION: IMPT for nasopharyngeal cancer patients is feasible with mild acute toxicity. Treatment outcomes are promising despite the high percentage of advanced disease in this group.
- MeSH
- celková dávka radioterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory nosohltanu * radioterapie MeSH
- následné studie MeSH
- nasofaryngeální karcinom radioterapie MeSH
- protonová terapie * škodlivé účinky MeSH
- protony MeSH
- radioterapie s modulovanou intenzitou škodlivé účinky MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Klíčová slova
- olaparib, toripalimumab, pemborolizumab, OlympiA, JUPITER-02, OUTBACK, VISION, KEYNOTE-564, CheckMate 648,
- MeSH
- adjuvantní chemoterapie MeSH
- antitumorózní látky terapeutické užití MeSH
- imunoterapie MeSH
- karcinom z renálních buněk farmakoterapie MeSH
- karcinom farmakoterapie MeSH
- klinická studie jako téma * MeSH
- lidé MeSH
- nádory děložního čípku farmakoterapie MeSH
- nádory prostaty rezistentní na kastraci farmakoterapie MeSH
- nádory prsu farmakoterapie MeSH
- nádory farmakoterapie MeSH
- nasofaryngeální karcinom farmakoterapie MeSH
- radiofarmaka terapeutické užití MeSH
- skvamózní karcinom jícnu farmakoterapie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- zprávy MeSH
